Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2061]

Rituximab versus idelalisib in refractory CLL

Prof John Gribben - Queen Mary University London, London, UK; Prof Peter Hillmen - St James’ University Hospital, Leeds, UK

$Rituximab versus idelalisib in refractory CLL ( Prof John Gribben - Queen Mary University London, London, UK; Prof Peter Hillmen - St James’ University Hospital, Leeds, UK )$

New agents extend progression-free survival in double refractory myeloma

Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta, USA

$New agents extend progression-free survival in double refractory myeloma ( Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta, USA )$

Aspirin analogues developed for anti-cancer effects on leukaemia

Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK

Aspirin analogues developed for anti-cancer effects on leukaemia ( Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK )

Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients

Dr Valentin Goede - University of Cologne, Cologne, Germany

Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients ( Dr Valentin Goede - University of Cologne, Cologne, Germany )

New drug OTX15 shows early promise in fighting acute myeloid leukaemia

Dr Esteban Cvitkovic - Oncoethix, Lausanne, Switzerland

New drug OTX15 shows early promise in fighting acute myeloid leukaemia ( Dr Esteban Cvitkovic - Oncoethix, Lausanne, Switzerland )

Personalisation of leukaemia treatment using genome sequencing

Dr Giovanni Martinelli - University of Bologna, Bologna, Italy

Personalisation of leukaemia treatment using genome sequencing ( Dr Giovanni Martinelli - University of Bologna, Bologna, Italy )

Phase I trial shows the benefits of OTX015 in treating blood cancer

Dr Esteban Cvitkovic - Oncoethix, Lausanne, Switzerland

Phase I trial shows the benefits of OTX015 in treating blood cancer ( Dr Esteban Cvitkovic - Oncoethix, Lausanne, Switzerland )

Role of AORTIC in dealing with rising cancer rates in Africa

North American Vice president of AORTIC

Role of AORTIC in dealing with rising cancer rates in Africa ( North American Vice president of AORTIC )

AG-221 shows clinical activity in acute myeloid leukaemia

Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA

AG-221 shows clinical activity in acute myeloid leukaemia ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )

Effective use of ibrutinib in the treatment of ABC lymphoma tumours

Dr Louis Staudt - National Cancer Institute, Bethesda, USA

Effective use of ibrutinib in the treatment of ABC lymphoma tumours ( Dr Louis Staudt - National Cancer Institute, Bethesda, USA )

The 1st Immunotherapy of Cancer Conference (ITOC)

Prof Heinz Zwierina - Innsbruck Medical University, Innsbruck, Austria

The 1st Immunotherapy of Cancer Conference (ITOC) ( Prof Heinz Zwierina - Innsbruck Medical University, Innsbruck, Austria )

Reasons for combining immunotherapy with chemo to enhance anti tumour response

Prof Angus Dalgleish - St George's, University of London, London, UK

Reasons for combining immunotherapy with chemo to enhance anti tumour response ( Prof Angus Dalgleish - St George's, University of London, London, UK )

More from ecancer